Proline dehydrogenase (oxidase) in cancer
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Proline dehydrogenase (oxidase, PRODH/POX), the first enzyme in the proline degradative pathway, plays a special role in tumorigenesis and tumor development. Proline metabolism catalyzed by PRODH/POX is closely linked with the tricarboxylic acid (TCA) cycle and urea cycle. The proline cycle formed by the interconversion of proline and Δ 1‐pyrroline‐5‐carboxylate (P5C) between mitochondria and cytosol interlocks with pentose phosphate pathway. Importantly, by catalyzing proline to P5C, PRODH/POX donates electrons into the electron transport chain to generate ROS or ATP. In earlier studies, we found that PRODH/POX functions as a tumor suppressor to initiate apoptosis, inhibit tumor growth, and block the cell cycle, all by ROS signaling. It also suppresses hypoxia inducible factor signaling by increasing α‐ketoglutarate. During tumor progression, PRODH/POX is under the control of various tumor‐associated factors, such as tumor suppressor p53, inflammatory factor peroxisome proliferator‐activated receptor gamma (PPARγ), onco‐miRNA miR‐23b*, and oncogenic transcription factor c‐MYC. Recent studies revealed the two‐sided features of PRODH/POX‐mediated regulation. Under metabolic stress such as oxygen and glucose deprivation, PRODH/POX can be induced to serve as a tumor survival factor through ATP production or ROS‐induced autophagy. The paradoxical roles of PRODH/POX can be understood considering the temporal and spatial context of the tumor. Further studies will provide additional insights into this protein and on its metabolic effects in tumors, which may lead to new therapeutic strategies. © 2012 International Union of Biochemistry and Molecular Biology, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 2×
“Recent studies from other laboratories demonstrated that p53 also regulates metabolic pathways to inhibit oncogenic transformation and promote tumor cell survival [28,29].”
A model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“PPARc belongs to the nuclear hormone receptor superfamily and functions as a ligand-dependent transcription factor [30].”
Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein
Cao, Y., & Klionsky, D. J. (2007) · Cell Research · doi:10.1038/cr.2007.78 · Cited by 541 · cited 1×
“Beclin-1 is one of the central regulators of autophagy in mammalian cells [56].”
Inhibition of Hypoxia-inducible Factor (HIF) Hydroxylases by Citric Acid Cycle Intermediates
Koivunen, P., Hirsilä, M., Remes, A. M., Hassinen, I. E., Kivirikko, K. I., & Myllyharju, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610415200 · Cited by 521 · cited 1×
“Furthermore, several TCA cycle intermediates, such as succinate and fumarate, inhibit PHD activity and stabilize HIF-1 signaling [22,23].”
Zarse, K., Schmeisser, S., Groth, M., Priebe, S., Beuster, G., Kuhlow, D., Guthke, R., Platzer, M., Kahn, C. R., & Ristow, M. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.02.013 · Cited by 430 · cited 1×
“elegans in which apoptotic signals may also trigger a survival response is another interesting model confirming the prosurvival role of PRODH/POX and proline metabolism [42].”
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336 · cited 1×
“Epidemiologic studies in the patients with type 2 diabetes indicate that TZDs significantly decreased the risk of lung cancer [35].”
The metabolism of proline, a stress substrate, modulates carcinogenic pathways
Phang, J. M., Donald, S. P., Pandhare, J., & Liu, Y. (2008) · Amino Acids · doi:10.1007/s00726-008-0063-4 · Cited by 252 · cited 1×
“The result showed that DHEA did significantly decrease the PRODH/POX-dependent increase of the cellular ATP [49].”
Proline oxidase functions as a mitochondrial tumor suppressor in human cancers
Liu, Y., Borchert, G. L., Donald, S. P., Diwan, B. A., Anver, M., & Phang, J. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1223 · Cited by 132 · cited 7×
“PRODH/POX protein levels showed more striking decreases than transcript levels [20,24], indicating that PRODH/POX may be regulated at the post-transcriptional level.”
InfluentialSelf-citation
Cited by
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Targeting cell cycle regulation in cancer therapy
Diaz-Moralli, S., Tarrado-Castellarnau, M., Miranda, A., & Cascante, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.011 · Cited by 361
Gào, X., & Schöttker, B. (2017) · Oncotarget · doi:10.18632/oncotarget.17128 · Cited by 147
Clavijo-Cornejo, D., Martínez-Flores, K., Silva-Luna, K., Martínez-Nava, G. A., Fernández-Torres, J., Zamudio-Cuevas, Y., Guadalupe Santamaría-Olmedo, M., Granados-Montiel, J., Pineda, C., & López-Reyes, A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1472567 · Cited by 65
Metadata
- Authors
- Liu, W., & Phang, J. M.
- Venue
- BioFactors
- Publisher
- Wiley
- Published
- 2012-08-08
- Volume
- 38
- Issue
- 6
- Pages
- 398-406
- ISSN
- 0951-6433 (ISSN-L)
- 1872-8081
- OpenAlex
- W2016428000
- Cited by
- 88
- References
- 9
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.